Aceso Life Science Group Limited (Stock Code: 00474) announced the full repayment of a loan previously demanded by a Hong Kong-based commercial bank. The initial demand letter, issued on 23 April 2025, sought repayment of approximately HK$352 million in outstanding indebtedness.
According to the latest announcement dated 28 October 2025, the entire amount has now been settled in full. The company’s statement advised shareholders and potential investors to exercise caution when dealing in its shares.
The board currently comprises two executive directors, one non-executive director, and three independent non-executive directors.